GSK received US approval for Hibsago, adding a chronic hepatitis B treatment it can offer to patients. No sales or patient-use results are reported, but the approval expands its available treatment options.
This gives GSK a new approved treatment it can offer in the United States. The story gives no sales or patient-use results, so the size of the benefit is not yet known. Still, approval and access to patients make the news positive for GSK.
Follow GSK (GSK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GSK